Medical Device News Magazine

PharmaJet Presents Multiple Partners’ Data Demonstrating Superior Immunogenicity With Their Needle-free Systems at BIO International Convention

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

PharmaJet®, a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, today announced that their latest research results were presented at the BIO International Convention in June. The presentation, entitled Improved Vaccine and Therapeutic Performance…without the Jab, was presented by Paul LaBarre, MS, MBA, Vice President Global Business Development at PharmaJet, Inc.

There is a growing body of evidence that shows needle-free delivery can make injectables perform better. PharmaJet’s Needle-free Injection Systems (NFIS) can improve performance by providing a similar, and often better, immunogenicity in the patient with a strong antibody and T-cell response, when used to administer nucleic acid-based vaccines and therapeutics. Currently there are 18 partner publications that show equivalent or better effectiveness when using the PharmaJet NFIS compared with either electroporation or traditional needle and syringe. These include 11 studies comparing delivery methods for DNA vaccines, 1 for an mRNA vaccine, and 2 for live attenuated vaccines.1

This presentation highlighted published collaborator data from three partners that found increased immunogenicity when using the PharmaJet Systems to deliver nucleic acid-based vaccines:

  1. Zydus Lifesciences recently conducted a non-human primate study on their Plasmid DNA-based COVID-19 vaccine. They saw higher antibody responses with the Tropis® ID System as compared to needle and syringe delivery and better protection from challenge with the virus. After getting similar results in their phase I studies, they progressed to phase II and III exclusively using PharmaJet’s Needle-free Systems and are now commercializing their product.2
  2. INRA compared the results of DNA plasmids administered with needle-free jet injection or electroporation. The Tropis System induced higher luciferase expression, was more potent to transduce skin cells and induced lower inflammatory responses.3
  3. Curevac compared needle and syringe versus needle-free delivery at both ID (using the PharmaJet Tropis® System) and IM (using the PharmaJet Stratis® System) depths for their candidate mRNA-based vaccine that encodes rabies antigen and found the candidate vaccine boosted functional antibodies when humans were injected with a needle-free device but not when injected by a needle-syringe.4

“Our worldwide partner list is quickly growing, and feedback has been very positive,” said Chris Cappello, President and Chief Executive Officer, PharmaJet, Inc. “With over 80 studies currently in progress with 55 pharmaceutical partners, we’ve learned that a broad variety of pharmaceutical products can be delivered needle-free including nucleic acid-based, inactivated, subunit, live attenuated and viral vector vaccines. We are aiming to increase our pipeline 3-fold in the next several years.”


1 Data on file

2 Momin, et al 2021, Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

3 Bernelin-Cottet, et al, A DNA Prime Immuno-Potentiates a Modified Live Vaccine against the Porcine Reproductive and Respiratory Syndrome Virus but Does Not Improve Heterologous Protection

4 Alberer, et al 2017, Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.